Entrada Therapeutics (TRDA) news
Recent news
Entra decided to start share buyback program of up to NOK 200M
AInvest Wire · 4h agoEntra 3Q net oper income NOK 709M, est. NOK 714M
AInvest Wire · 4h agoEntra 3Q net loss NOK 450.0M, est. profit NOK 268M
Entra reported a net loss of NOK 450.0 million for the third quarter, significantly below the estimated profit of NOK 268 million. This outcome contrasts with the broader performance of the technology sector, where Microsoft, for example, reported strong results in its third quarter of fiscal 2023,…
AInvest Wire · 4h agoEntra 3Q rental income NOK 782M est. NOK 778.8M
AInvest Wire · 4h agoEntrada Therapeutics - Elevate-45-201 cohort 2 enrollment complete; data at 10 mg/kg expected first half 2027
Entrada Therapeutics has announced that enrollment for Cohort 2 of its ELEVATE-45-201 clinical trial has been completed. This trial is part of the company’s ongoing efforts to develop exon-skipping therapies for Duchenne muscular dystrophy (DMD) in patients amenable to exon 45 skipping. The cohort…
AInvest Wire · 22h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.